Literature DB >> 17021103

Use of a multiantigen detection algorithm for diagnosis of Kaposi's sarcoma-associated herpesvirus infection.

A Scott Laney1, Jonathan S Peters, Susan M Manzi, Lawrence A Kingsley, Yuan Chang, Patrick S Moore.   

Abstract

The ability to readily and accurately diagnose Kaposi's sarcoma-associated herpesvirus (KSHV, or human herpesvirus 8) infection in individuals remains a demanding task. Among the available diagnostic methods, sensitivities and specificities range widely, and many are inadequate for large-scale screening studies. We examined a serological algorithm for detecting KSHV in human sera having high sensitivity and specificity. This method uses previously described open reading frame (ORF) K8.1 and ORF65 peptide-based enzyme-linked immunosorbent assays and a novel purified recombinant full-length LANA1 protein. We generated two multiantigen algorithms: one that maximized sensitivity and one that maximized specificity. These serological algorithms were then used to evaluate seroprevalence rates among populations of clinical and epidemiological importance. The serological algorithms yielded sensitivities of 96% and 93% and specificities of 94% and 98% for the more sensitive and specific algorithms, respectively. Among kidney donors, seroprevalence was low, 4.0% (2/50), and similar to that of blood donors (P = 0.46; odds ratio [OR], 1.4; confidence interval [CI], 0.14 to 7.9) using the highly specific algorithm. Using the sensitive algorithm, 8.0% (4/50) were infected compared to 6.4% (16/250) observed among blood donors (OR, 1.3; CI, 0.41 to 4.0; P = 0.43). Among subjects requiring bone marrow transplantation, seroprevalence rates were not elevated compared to those of blood donors (OR, 2.0; 95% CI, 0.10 to 122.9; P = 0.50). Because the need for high-quality KSHV detection methods are warranted and because questions remain about the optimal methods for assessing KSHV infection in individuals, we propose a systematic approach to standardize and optimize the assessment of KSHV infection rates using a combination of established and novel serological assays and methods.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17021103      PMCID: PMC1594766          DOI: 10.1128/JCM.00191-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  48 in total

1.  Posttransplantation plasmacytic proliferations related to Kaposi's sarcoma-associated herpesvirus.

Authors:  A Y Matsushima; J A Strauchen; G Lee; E Scigliano; E E Hale; M T Weisse; D Burstein; O Kamel; P S Moore; Y Chang
Journal:  Am J Surg Pathol       Date:  1999-11       Impact factor: 6.394

2.  Outcome of kidney transplant recipients with previous human herpesvirus-8 infection.

Authors:  C Francès; C Mouquet; A G Marcelin; S Barete; R Agher; D Charron; H Benalia; N Dupin; J C Piette; M O Bitker; V Calvez
Journal:  Transplantation       Date:  2000-05-15       Impact factor: 4.939

3.  Identifying human herpesvirus 8 infection: performance characteristics of serologic assays.

Authors:  E A Engels; D Whitby; P B Goebel; A Stossel; D Waters; A Pintus; L Contu; R J Biggar; J J Goedert
Journal:  J Acquir Immune Defic Syndr       Date:  2000-04-01       Impact factor: 3.731

4.  Comparison of serologic assays and PCR for diagnosis of human herpesvirus 8 infection.

Authors:  T J Spira; L Lam; S C Dollard; Y X Meng; C P Pau; J B Black; D Burns; B Cooper; M Hamid; J Huong; K Kite-Powell; P E Pellett
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

5.  Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients.

Authors:  C Parravicini; S J Olsen; M Capra; F Poli; G Sirchia; S J Gao; E Berti; A Nocera; E Rossi; G Bestetti; M Pizzuto; M Galli; M Moroni; P S Moore; M Corbellino
Journal:  Blood       Date:  1997-10-01       Impact factor: 22.113

Review 6.  Human herpesvirus 8 and Kaposi's sarcoma in persons infected with human immunodeficiency virus.

Authors:  J W Gnann; P E Pellett; H W Jaffe
Journal:  Clin Infect Dis       Date:  2000-04       Impact factor: 9.079

7.  Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients.

Authors:  M Luppi; P Barozzi; G Santagostino; R Trovato; T F Schulz; R Marasca; D Bottalico; L Bignardi; G Torelli
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

8.  Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men.

Authors:  N H Dukers; N Renwick; M Prins; R B Geskus; T F Schulz; G J Weverling; R A Coutinho; J Goudsmit
Journal:  Am J Epidemiol       Date:  2000-02-01       Impact factor: 4.897

9.  Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation.

Authors:  M Luppi; P Barozzi; T F Schulz; R Trovato; A Donelli; F Narni; J Sheldon; R Marasca; G Torelli
Journal:  Blood       Date:  2000-10-01       Impact factor: 22.113

10.  Sexual transmission and the natural history of human herpesvirus 8 infection.

Authors:  J N Martin; D E Ganem; D H Osmond; K A Page-Shafer; D Macrae; D H Kedes
Journal:  N Engl J Med       Date:  1998-04-02       Impact factor: 91.245

View more
  16 in total

1.  Gender differences in Kaposi's sarcoma-associated herpesvirus infection in a population with schistosomiasis in rural China.

Authors:  Bishi Fu; Rongge Yang; Fan Xia; Baolin Li; Xinxing Ouyang; Shou-Jiang Gao; Linding Wang
Journal:  Jpn J Infect Dis       Date:  2012-07       Impact factor: 1.362

2.  Quantitative determinations of anti-Kaposi sarcoma-associated herpesvirus antibody levels in men who have sex with men.

Authors:  Emile Gogineni; Vickie Marshall; Wendell Miley; Ahmad Bayat; Denise Whitby; Joseph A Kovacs; Peter D Burbelo
Journal:  Diagn Microbiol Infect Dis       Date:  2013-03-28       Impact factor: 2.803

3.  Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA.

Authors:  Georgina L Mbisa; Wendell Miley; Christine J Gamache; William K Gillette; Dominic Esposito; Ralph Hopkins; Michael P Busch; George B Schreiber; Richard F Little; Robert Yarchoan; Betty A Ortiz-Conde; Nazzarena Labò; Denise Whitby
Journal:  J Immunol Methods       Date:  2010-03-04       Impact factor: 2.303

4.  Prevalence of human herpesvirus 8 and hepatitis C virus in a rural community with a high risk for blood-borne infections in central China.

Authors:  T Zhang; N He; Y Ding; K Crabtree; V Minhas; C Wood
Journal:  Clin Microbiol Infect       Date:  2011-03       Impact factor: 8.067

5.  Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy.

Authors:  Moraima Guadalupe; Brad H Pollock; Steven Westbrook; Spencer Redding; Delia Bullock; Gregory Anstead; Brian K Agan; Vincent C Marconi; Sharon Barbieri; Vidya Sankar; Jennifer Rebeles; Yvette Flahive; John Schoolfield; Linding Wang; Xiufen Lei; Dorothy Dow; Chih-Ko Yeh; Howard Dang; Anthony J Infante; Shou-Jiang Gao
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

Review 6.  [Humanes herpesvirus 8 (HHV-8) and Kaposi sarcoma].

Authors:  C Lebbé
Journal:  Hautarzt       Date:  2008-01       Impact factor: 0.751

7.  Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays.

Authors:  Yanis L Tolstov; Diana V Pastrana; Huichen Feng; Jürgen C Becker; Frank J Jenkins; Stergios Moschos; Yuan Chang; Christopher B Buck; Patrick S Moore
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

8.  Development of whole-virus multiplex luminex-based serological assays for diagnosis of infections with kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 homologs in macaques.

Authors:  Jonathan T Ryan; Timothy M Rose
Journal:  Clin Vaccine Immunol       Date:  2013-01-23

9.  Four-antigen mixture containing v-cyclin for serological screening of human herpesvirus 8 infection.

Authors:  Peter D Burbelo; Hannah P Leahy; Sandra Groot; Lisa R Bishop; Wendell Miley; Michael J Iadarola; Denise Whitby; Joseph A Kovacs
Journal:  Clin Vaccine Immunol       Date:  2009-03-04

Review 10.  Targeting mitotic chromosomes: a conserved mechanism to ensure viral genome persistence.

Authors:  Katherine M Feeney; Joanna L Parish
Journal:  Proc Biol Sci       Date:  2009-01-20       Impact factor: 5.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.